Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme

Showing 101 to 150 of 258

TitleReference numberPublishedLast updated
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitorTA670
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancerTA668
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancerTA660
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)TA662
Testing strategies for Lynch syndrome in people with endometrial cancerDG42
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapyTA655
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancerTA653
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancerTA654
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancerTA643
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancerTA638
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancerTA639
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)TA635
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancerTA632
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancerTA628
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)TA618
Irreversible electroporation for primary liver cancerIPG664
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumabTA612
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancerTA611
Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancerIPG659
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancerTA595
Transurethral laser ablation for recurrent non-muscle-invasive bladder cancerIPG656
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancerTA584
Enzalutamide for hormone-relapsed non-metastatic prostate cancerTA580
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinibTA571
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancerTA569
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA563
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)TA560
Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancerIPG638
Vandetanib for treating medullary thyroid cancerTA550
Padeliporfin for untreated localised prostate cancerTA546
Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancerIPG628
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodineTA535
Alectinib for untreated ALK-positive advanced non-small-cell lung cancerTA536
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancerTA531
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancerTA529
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapyTA530
Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and overNG36
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancerIPG614
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapyTA520
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimenTA515
Cabozantinib for treating medullary thyroid cancerTA516
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancerTA509
Pancreatic cancer in adults: diagnosis and managementNG85
Intrabeam radiotherapy system for adjuvant treatment of early breast cancerTA501
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancerTA503
Ceritinib for untreated ALK-positive non-small-cell lung cancerTA500
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA495
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA496
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxaneTA458
Tests in secondary care to identify people at high risk of ovarian cancerDG31

Results per page

  1. 10
  2. 25
  3. 50
  4. All